SCHAFFHAUSEN, CH / ACCESSWIRE / April 5, 2023 / Occlutech Holding AG Occlutech Holding AG (“Occlutech”), one of the world’s leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million. Bonds amounting to EUR 20 […]
Financial
AVS’s Pulsatile Intravascular Lithotripsy Technology Attracts an Additional $8.8M to Close $28.8M Series B Round
BioStar Capital led the round with CUE Growth Partners BOSTON, April 4, 2023 – AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it closed an additional $8.8 million in new financing, bringing its Series B […]
Cardiovascular Clinical Sciences Names Dr. Jing Dai as New Head of Cardiac Core Lab
Cardiovascular Imaging Expert to Lead Core Lab Services in Support of Clinical Trials BOSTON, April 3, 2023 /PRNewswire/ — As cardiac imaging becomes more integrated in both clinical practice and research, Cardiovascular Clinical Sciences (CCS) announced today the appointment of Dr. Jing Dai as the new Director of Core Lab Operations.Dr. Dai is a […]
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on April 1, 2023 that were approved by the Compensation Committee of its Board of […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to […]
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth […]
SANUWAVE Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
EDEN PRARIE, MN, April 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “We are very pleased with the […]
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates. “We continued to advance our cardiovascular […]
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. […]
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced financial results for the fourth quarter and full year ended December 31, 2022. Company Updates Announced the progression of its […]



